Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
March 2018
-
Key ReleaseNovartis annonce des changements au sein de son Comité de direction afin de soutenir ses priorités stratégiquesBertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN…
-
Media ReleaseNovartis expands alliance with Science 37 to advance virtual clinical trials programNovartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model Agreement builds on our long-standing investment in and…
-
Media ReleaseNovartis' Xolair® recommended in new global chronic urticaria guidelineXolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Board of Directors at the Annual General MeetingShareholders approve 21st consecutive dividend increase to CHF 2.80 (+2%) per share for 2017; representing a 3.6% yield and approximately 67% payout of free cash flow Dr. Joerg Reinhardt…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée généraleLes actionnaires approuvent la 21e hausse consécutive du dividende, à CHF 2,80 (+2 %) par action au titre de l'exercice 2017, soit un rendement de 3,6 % et une distribution du free cash-…
-
Media ReleaseNovartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des VerwaltungsratsAktionäre genehmigen für 2017 die 21. Dividendenerhöhung in Folge auf CHF 2,80 pro Aktie (+2%) - dies entspricht einer Rendite von 3,6% und einer Ausschüttungsquote von rund 67% des Free Cashflow…
-
Media ReleaseNovartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosisNovartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis'…
February 2018
-
Media ReleaseAveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results– On track to request pre-BLA meeting with FDA in Q2 2018 – – Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of…
-
Media ReleaseTreatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflationUltibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to…
-
Media ReleaseAveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating ResultsConference call and webcast on February 27 at 4:30 p.m. EST CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments…
-
Media ReleaseNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasisTwo thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] Findings show absolute PASI <=1/…
-
Media ReleaseNovartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasisMajority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1] Scalp psoriasis affects 60 million…
Pagination
- ‹ Previous page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- …
- 100
- › Next page